1_applicationBioMedicales
π Science and technology
Lasers: promising applications for research and beyond

How to achieve deeper treatment of tumours with laser-plasma acceleration

with Isabelle Dumé, Science journalist
On June 29th, 2022 |
5min reading time
Alessandro Flacco
Alessandro Flacco
Associate professor at ENSTA Paris (IP Paris)
Key takeaways
  • Laser-plasma accelerators propel high-energy particles over short distances using intense, ultra-short pulses of laser light.
  • Ionising radiation is used in medicine for many purposes: from imaging to diagnosis and treatment of cancers.
  • In radiotherapy the toxicity of ionising radiation on living organisms is used, taking advantage of the different capacity to repair the damage caused to tumour cells and those caused to surrounding healthy cells.
  • Studies have also begun on VHEE (“very high energy electrons”), which theoretically allow a more complete and deeper treatment of tumours.

Laser-plasma accel­er­at­ors (LPA) pro­pel high-energy particles over short dis­tances thanks to intense, ultrashort pulses of laser light. These accel­er­at­ors can provide high-qual­ity particle beams (of elec­trons, pro­tons, and X‑ray photons) for radio-bio­lo­gic­al stud­ies that will help sci­ent­ists bet­ter under­stand how radi­ation dam­ages DNA and, ulti­mately, optim­ise can­cer treat­ments that make use of ion­ising radiation.

Recent stud­ies have shown that the bio­lo­gic­al effect of radi­ation depends not only on the total dose delivered, but also the time and the rate over which it is delivered. At the LOA (Labor­at­ory of Applied Optics), we are study­ing the effect of ultra-high dose rates in order to devel­op irra­di­ation pro­to­cols cap­able of increas­ing the dif­fer­en­tial response between healthy and can­cer­ous cells.

The lasers we use pro­duce very short pulses, in the pico­second (10-12 s) or femto­second (10-15 s) range and are very intense – so much so that when a laser pulse strikes the tar­get mater­i­al, it imme­di­ately ion­ises it, trans­form­ing it into a plasma, a state of mat­ter in which elec­trons and ions form a kind of “soup” with a col­lect­ive motion. Thus, detached from their nuc­lei, the elec­trons react to the laser field through the plasma.

In the case of a very dense plasma, in which the laser fails to propag­ate, the elec­trons escap­ing from the tar­get cause it to explode, thus accel­er­at­ing the ions in it. The res­ult: ions in the mega-elec­tron­volts (MeV) energy range are pro­duced over lengths as short as millimetres.

In the case of a low-dens­ity plasma, the propaga­tion of the laser pulse pro­duces a wake wave behind it that propag­ates at the speed of light. The elec­trons trapped in this wave are accel­er­ated – like a surfer on a wave – and thus gain energy. Elec­tric field gradi­ents as high as those pro­duced by this strategy (around (100 GeVm-1) are not pos­sible with con­ven­tion­al struc­tures (radio fre­quency cav­it­ies), which can reach about just 0.1 GeVm-1.

Ion­ising radi­ation is used in medi­cine for many pur­poses: from ima­ging to dia­gnos­is and can­cer treat­ment. There are a range of pos­sible ther­apies based on the harm­ful effect of this radi­ation on liv­ing organ­isms. Elec­tron beams dam­age can­cer cells in a very sim­il­ar way to high-energy photons, which are the most com­mon radio­ther­apy mod­al­ity in clin­ic­al prac­tice. This is because high-energy elec­trons con­vert much of their kin­et­ic energy into X‑ray photons by “bremsstrahlung”, which trig­gers a cas­cade of elec­trons, positrons, and photons, and also ion­ises the mater­i­al by inelast­ic col­li­sions. It is the lat­ter that even­tu­ally dam­ages can­cer cells, either by dir­ectly ion­ising the DNA or by indir­ectly cre­at­ing rad­ic­als that dam­age it.

Differences in radioresistance between healthy and cancer cells

In any type of ther­apy, there is a dif­fer­en­tial between the desired effect and the unin­ten­ded side effects. In radio­ther­apy, the tox­icity of ion­ising radi­ation on liv­ing organ­isms is exploited. Basic­ally, healthy cells have a slightly high­er radiores­ist­ance than can­cer cells. This dif­fer­ence allows the devel­op­ment of ion­ising radi­ation dose deliv­ery pro­to­cols in which the harm­ful effect on healthy cells is less import­ant than the destruct­ive effect on tumour cells.

For laser-accel­er­ated particles, there are two aspects. The first is related to the qual­ity of the particles used. Cur­rently, the most com­monly used particles in radio medi­cine are photons and pro­tons, but each has very dif­fer­ent char­ac­ter­ist­ics of dose deliv­ery in bio­lo­gic­al tis­sue. Photons deliv­er their energy accord­ing to a decreas­ing expo­nen­tial curve, so that there is a max­im­um dose at the tis­sue sur­face and a min­im­um at depth. Irra­di­ation pro­to­cols for deep tumours must there­fore be designed in such a way as not to exceed cer­tain doses at entry and to achieve a thera­peut­ic dose at depth, which is not easy.

Photons are widely used in radio­ther­apy because they are easy to pro­duce, where­as pro­tons are just begin­ning to be used because they require much lar­ger machines. For example, a photon radio­ther­apy machine requires a room of about 20 m2 in sur­face area, where­as pro­ton ther­apy, which requires a cyclo­tron, must be installed in a build­ing sev­er­al hun­dred square metres in size.

Elec­trons, on the oth­er hand, have been little used in the past for sev­er­al reas­ons. First, they have a rather flat dose deliv­ery curve. They were also more dif­fi­cult to accel­er­ate than photons.

The flash effect

This situ­ation changed with the dis­cov­ery of the flash effect, a phe­nomen­on observed as early as the 1970s and redis­covered at Orsay in the 2000s. Research­ers there found that the same thera­peut­ic dose of ion­ising radi­ation has a dif­fer­ent effect depend­ing on the time scale over which it is delivered.

Research­ers found that the same thera­peut­ic dose of ion­ising radi­ation has a dif­fer­ent effect depend­ing on the time scale over which it is delivered.

The whole field of radio­ther­apy is based on the pos­tu­late that for the same dose, we have an equal response. It’s the same as for a drug, like a dose of paracetamol, for example: the dose determ­ines the bio­lo­gic­al effect. What we found is that if you deliv­er the same dose over an extremely short peri­od of time, the thera­peut­ic effect changes. Healthy tis­sue seems to be much more res­ist­ant to the same dose if it is applied over a very short peri­od of time, while the sens­it­iv­ity of tumour tis­sue remains unchanged. This means that if this thera­peut­ic dose is delivered over 50 ms rather than 10 minutes, noth­ing changes for the tumour cells but the dam­age to healthy tis­sue is con­sid­er­ably reduced.

The flash effect thus allows for a much more effect­ive and effi­cient treatment.

The first exper­i­ments on the effect (between 2016 and 2020) were car­ried out with low energy elec­trons (LEE), which have an energy of less than 5 MeV, simply because these elec­trons were the most read­ily avail­able. They can only pen­et­rate to a depth of a few mil­li­metres into the tis­sue, and there­fore can­not be used to treat deep tumours.

Very high energy electrons and fast fractionation

We have now turned our atten­tion to very high energy elec­trons (VHEE), that is, elec­trons with ener­gies above 150 MeV, which have been little stud­ied in the past. The beams of these elec­trons pen­et­rate deep into tis­sue and can treat tumours that photon irra­di­ation can­not reach. How­ever, a lin­ac-based VHEE treat­ment sys­tem, for example, would have to be com­pact enough to fit in a hos­pit­al treat­ment room to be com­pet­it­ive with photons.

VHEEs are likely to be more expens­ive to pro­duce than photons, but cheap­er than pro­tons. Depth-dose curves show that in addi­tion to deliv­er­ing the dose at depth, VHEEs should also be more resi­li­ent to unex­pec­ted tis­sue inhomo­gen­eit­ies than X‑rays.

VHEEs can also allow deep tumours to be pre­cisely tar­geted by con­cen­trat­ing the dose in a small volume. This dose can be con­trolled, which may be an advant­age for the treat­ment of radi­ation-res­ist­ant tumours. The abil­ity to deliv­er the dose in a small spot can also bene­fit ultra-pre­ci­sion ther­apy, where very small areas of tis­sue need to be irra­di­ated. In addi­tion, the very low dose at entry and the low distal and prox­im­al doses of VHEE focused beams can help min­im­ise dam­age to healthy tis­sue and sens­it­ive organs.

Clin­ic­al applic­a­tions of this type of ther­apy are still some way off and much work still remains to be done to devel­op the laser and accel­er­at­or tech­no­logy to make it suit­able for the real world. We have called this irra­di­ation mod­al­ity « fast frac­tion­a­tion » and have star­ted to study its bio­lo­gic­al effects. Pre­lim­in­ary res­ults show that the rate of laser pulses has an effect on the tox­icity of ion­ising radi­ation: it is not only the dur­a­tion of the flash but also the total dose of a single pulse that has an effect on tox­icity. We are not able to explain the mech­an­isms behind the flash effect as yet, but our stud­ies have only just begun. One thing is cer­tain, it holds great prom­ise for the devel­op­ment of highly effect­ive radiotherapy.

Références:

https://​loa​.ensta​-par​is​.fr/​f​r​/​a​c​c​ueil/

Support accurate information rooted in the scientific method.

Donate